tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ORKA Stock Latest News

Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy
The FlyClear Street says AbbVie move further validates Oruka Therapeutics’ strategy
16d ago
GSK
ABBV
Oruka Therapeutics price target raised to $45 from $42 at Wedbush
PremiumThe Fly
Oruka Therapeutics price target raised to $45 from $42 at Wedbush
1M ago
ORKA
Oruka Therapeutics price target raised to $71 from $46 at Clear Street
PremiumThe Fly
Oruka Therapeutics price target raised to $71 from $46 at Clear Street
1M ago
ORKA
Oruka Therapeutics: Long-Acting IL-17 Platform Drives Upgraded Valuation and Buy Rating
PremiumRatings
Oruka Therapeutics: Long-Acting IL-17 Platform Drives Upgraded Valuation and Buy Rating
1M ago
ORKA
Oruka provides updates on Phase 1 trial of ORKA-002, EVERLAST-B ORKA-001 trial
PremiumThe Fly
Oruka provides updates on Phase 1 trial of ORKA-002, EVERLAST-B ORKA-001 trial
1M ago
ORKA
Oruka Therapeutics initiated with a Buy at UBS
PremiumThe FlyOruka Therapeutics initiated with a Buy at UBS
1M ago
ORKA
ORKA-001 Psoriasis Trial: Fresh Phase 2 Update and What It Means for Investors
Premium
Company Announcements
ORKA-001 Psoriasis Trial: Fresh Phase 2 Update and What It Means for Investors
2M ago
ORKA
Oruka Therapeutics initiated with an Overweight at Piper Sandler
Premium
The Fly
Oruka Therapeutics initiated with an Overweight at Piper Sandler
2M ago
ORKA
Oruka Therapeutics Appoints Christopher Martin to Board
PremiumCompany Announcements
Oruka Therapeutics Appoints Christopher Martin to Board
2M ago
8K
ORKA
Oruka Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Oruka Therapeutics Reports Q3 2025 Financial Results
3M ago
ORKA
Oruka Therapeutics price target raised to $63 from $56 at BTIG
PremiumThe Fly
Oruka Therapeutics price target raised to $63 from $56 at BTIG
3M ago
ORKA
Oruka Therapeutics initiated with a Buy at Jefferies
PremiumThe Fly
Oruka Therapeutics initiated with a Buy at Jefferies
3M ago
ORKA
Oruka Therapeutics: Promising Advancements in Monoclonal Antibodies Drive Buy Rating
PremiumRatingsOruka Therapeutics: Promising Advancements in Monoclonal Antibodies Drive Buy Rating
3M ago
ORKA
Oruka Therapeutics reports Q3 EPS (55c), consensus (52c)
Premium
The Fly
Oruka Therapeutics reports Q3 EPS (55c), consensus (52c)
3M ago
ORKA
ORKA Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ORKA Earnings this Week: How Will it Perform?
3M ago
ORKA
Oruka Therapeutics’ Promising Psoriasis Study: What Investors Need to Know
PremiumCompany Announcements
Oruka Therapeutics’ Promising Psoriasis Study: What Investors Need to Know
4M ago
ORKA
Oruka Therapeutics initiated with a Buy at Guggenheim
PremiumThe Fly
Oruka Therapeutics initiated with a Buy at Guggenheim
4M ago
ORKA
Oruka Therapeutics price target lowered to $40 from $45 at H.C. Wainwright
PremiumThe Fly
Oruka Therapeutics price target lowered to $40 from $45 at H.C. Wainwright
4M ago
ORKA
Oruka Therapeutics initiated with an Overweight at Barclays
PremiumThe Fly
Oruka Therapeutics initiated with an Overweight at Barclays
4M ago
ORKA
Oruka Therapeutics files to sell 39.43M shares of common stock for holders
PremiumThe FlyOruka Therapeutics files to sell 39.43M shares of common stock for holders
5M ago
ORKA
Promising Future for Oruka Therapeutics: Buy Rating Backed by ORKA-002’s Market Potential and Strategic Expansion
Premium
Ratings
Promising Future for Oruka Therapeutics: Buy Rating Backed by ORKA-002’s Market Potential and Strategic Expansion
5M ago
ORKA
Oruka Therapeutics’ ORKA-002: Promising Alternative with Competitive Edge in Hidradenitis Suppurativa and Psoriasis
Premium
Ratings
Oruka Therapeutics’ ORKA-002: Promising Alternative with Competitive Edge in Hidradenitis Suppurativa and Psoriasis
5M ago
ORKA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >